LetterLetter
Relapse and Remission in Children With Chronic Noninfectious Uveitis Treated With Methotrexate
Courtney McCracken, Jessica G. Shantha, Steven Yeh, Kirsten Jenkins, Kelly A. Rouster-Stevens, Scott R. Lambert, Sampath Prahalad, Carolyn Drews-Botsch and Sheila T. Angeles-Han
The Journal of Rheumatology August 2022, jrheum.220007; DOI: https://doi.org/10.3899/jrheum.220007
Courtney McCracken
Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia; Francis I. Proctor Foundation for Research in Ophthalmology, and Department of Ophthalmology University of California, San Francisco, San Francisco, California; Department of Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska; Children's Healthcare of Atlanta, Atlanta, Georgia; Department of Ophthalmology, Stanford University, Stanford, California; Department of Genetics, Emory University School of Medicine, Atlanta, Georgia; Department of Global and Community Health, George Mason University, Fairfax, Virginia; Division of Rheumatology and Pediatric Ophthalmology, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA.C. McCracken and J.G. Shantha contributed equally to this work. Research reported in this manuscript was supported by the National Eye Institute (NEI) Award Number K23EY021760 (STAH), K23EY030159 ( JGS), and the Rheumatology Research Foundation. STAH is also supported by NEI R01EY030521. SP is supported in part by a grant from the Marcus Foundation Inc., Atlanta. SY is a consultant for Santen and Clearside Biomedical, unrelated to this study. KARS is a consultant for Accordant, unrelated to this study. SP serves on the Macrophage Activation Syndrome Adjudication Committee for Novartis and is a Doximity Op-Med Fellow for 2021–22, unrelated to this study. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. S.T. Angeles-Han, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, 3333 Burnett Avenue, Cincinnati, OH 45229, USA; Department of Pediatrics, University of Cincinnati, Cincinnati, OH 45229, USA. Email: sheila.angeles-han@cchmc.org.
Jessica G. Shantha
Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia; Francis I. Proctor Foundation for Research in Ophthalmology, and Department of Ophthalmology University of California, San Francisco, San Francisco, California; Department of Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska; Children's Healthcare of Atlanta, Atlanta, Georgia; Department of Ophthalmology, Stanford University, Stanford, California; Department of Genetics, Emory University School of Medicine, Atlanta, Georgia; Department of Global and Community Health, George Mason University, Fairfax, Virginia; Division of Rheumatology and Pediatric Ophthalmology, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA.C. McCracken and J.G. Shantha contributed equally to this work. Research reported in this manuscript was supported by the National Eye Institute (NEI) Award Number K23EY021760 (STAH), K23EY030159 ( JGS), and the Rheumatology Research Foundation. STAH is also supported by NEI R01EY030521. SP is supported in part by a grant from the Marcus Foundation Inc., Atlanta. SY is a consultant for Santen and Clearside Biomedical, unrelated to this study. KARS is a consultant for Accordant, unrelated to this study. SP serves on the Macrophage Activation Syndrome Adjudication Committee for Novartis and is a Doximity Op-Med Fellow for 2021–22, unrelated to this study. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. S.T. Angeles-Han, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, 3333 Burnett Avenue, Cincinnati, OH 45229, USA; Department of Pediatrics, University of Cincinnati, Cincinnati, OH 45229, USA. Email: sheila.angeles-han@cchmc.org.
Steven Yeh
Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia; Francis I. Proctor Foundation for Research in Ophthalmology, and Department of Ophthalmology University of California, San Francisco, San Francisco, California; Department of Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska; Children's Healthcare of Atlanta, Atlanta, Georgia; Department of Ophthalmology, Stanford University, Stanford, California; Department of Genetics, Emory University School of Medicine, Atlanta, Georgia; Department of Global and Community Health, George Mason University, Fairfax, Virginia; Division of Rheumatology and Pediatric Ophthalmology, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA.C. McCracken and J.G. Shantha contributed equally to this work. Research reported in this manuscript was supported by the National Eye Institute (NEI) Award Number K23EY021760 (STAH), K23EY030159 ( JGS), and the Rheumatology Research Foundation. STAH is also supported by NEI R01EY030521. SP is supported in part by a grant from the Marcus Foundation Inc., Atlanta. SY is a consultant for Santen and Clearside Biomedical, unrelated to this study. KARS is a consultant for Accordant, unrelated to this study. SP serves on the Macrophage Activation Syndrome Adjudication Committee for Novartis and is a Doximity Op-Med Fellow for 2021–22, unrelated to this study. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. S.T. Angeles-Han, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, 3333 Burnett Avenue, Cincinnati, OH 45229, USA; Department of Pediatrics, University of Cincinnati, Cincinnati, OH 45229, USA. Email: sheila.angeles-han@cchmc.org.
Kirsten Jenkins
Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia; Francis I. Proctor Foundation for Research in Ophthalmology, and Department of Ophthalmology University of California, San Francisco, San Francisco, California; Department of Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska; Children's Healthcare of Atlanta, Atlanta, Georgia; Department of Ophthalmology, Stanford University, Stanford, California; Department of Genetics, Emory University School of Medicine, Atlanta, Georgia; Department of Global and Community Health, George Mason University, Fairfax, Virginia; Division of Rheumatology and Pediatric Ophthalmology, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA.C. McCracken and J.G. Shantha contributed equally to this work. Research reported in this manuscript was supported by the National Eye Institute (NEI) Award Number K23EY021760 (STAH), K23EY030159 ( JGS), and the Rheumatology Research Foundation. STAH is also supported by NEI R01EY030521. SP is supported in part by a grant from the Marcus Foundation Inc., Atlanta. SY is a consultant for Santen and Clearside Biomedical, unrelated to this study. KARS is a consultant for Accordant, unrelated to this study. SP serves on the Macrophage Activation Syndrome Adjudication Committee for Novartis and is a Doximity Op-Med Fellow for 2021–22, unrelated to this study. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. S.T. Angeles-Han, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, 3333 Burnett Avenue, Cincinnati, OH 45229, USA; Department of Pediatrics, University of Cincinnati, Cincinnati, OH 45229, USA. Email: sheila.angeles-han@cchmc.org.
Kelly A. Rouster-Stevens
Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia; Francis I. Proctor Foundation for Research in Ophthalmology, and Department of Ophthalmology University of California, San Francisco, San Francisco, California; Department of Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska; Children's Healthcare of Atlanta, Atlanta, Georgia; Department of Ophthalmology, Stanford University, Stanford, California; Department of Genetics, Emory University School of Medicine, Atlanta, Georgia; Department of Global and Community Health, George Mason University, Fairfax, Virginia; Division of Rheumatology and Pediatric Ophthalmology, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA.C. McCracken and J.G. Shantha contributed equally to this work. Research reported in this manuscript was supported by the National Eye Institute (NEI) Award Number K23EY021760 (STAH), K23EY030159 ( JGS), and the Rheumatology Research Foundation. STAH is also supported by NEI R01EY030521. SP is supported in part by a grant from the Marcus Foundation Inc., Atlanta. SY is a consultant for Santen and Clearside Biomedical, unrelated to this study. KARS is a consultant for Accordant, unrelated to this study. SP serves on the Macrophage Activation Syndrome Adjudication Committee for Novartis and is a Doximity Op-Med Fellow for 2021–22, unrelated to this study. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. S.T. Angeles-Han, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, 3333 Burnett Avenue, Cincinnati, OH 45229, USA; Department of Pediatrics, University of Cincinnati, Cincinnati, OH 45229, USA. Email: sheila.angeles-han@cchmc.org.
Scott R. Lambert
Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia; Francis I. Proctor Foundation for Research in Ophthalmology, and Department of Ophthalmology University of California, San Francisco, San Francisco, California; Department of Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska; Children's Healthcare of Atlanta, Atlanta, Georgia; Department of Ophthalmology, Stanford University, Stanford, California; Department of Genetics, Emory University School of Medicine, Atlanta, Georgia; Department of Global and Community Health, George Mason University, Fairfax, Virginia; Division of Rheumatology and Pediatric Ophthalmology, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA.C. McCracken and J.G. Shantha contributed equally to this work. Research reported in this manuscript was supported by the National Eye Institute (NEI) Award Number K23EY021760 (STAH), K23EY030159 ( JGS), and the Rheumatology Research Foundation. STAH is also supported by NEI R01EY030521. SP is supported in part by a grant from the Marcus Foundation Inc., Atlanta. SY is a consultant for Santen and Clearside Biomedical, unrelated to this study. KARS is a consultant for Accordant, unrelated to this study. SP serves on the Macrophage Activation Syndrome Adjudication Committee for Novartis and is a Doximity Op-Med Fellow for 2021–22, unrelated to this study. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. S.T. Angeles-Han, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, 3333 Burnett Avenue, Cincinnati, OH 45229, USA; Department of Pediatrics, University of Cincinnati, Cincinnati, OH 45229, USA. Email: sheila.angeles-han@cchmc.org.
Sampath Prahalad
Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia; Francis I. Proctor Foundation for Research in Ophthalmology, and Department of Ophthalmology University of California, San Francisco, San Francisco, California; Department of Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska; Children's Healthcare of Atlanta, Atlanta, Georgia; Department of Ophthalmology, Stanford University, Stanford, California; Department of Genetics, Emory University School of Medicine, Atlanta, Georgia; Department of Global and Community Health, George Mason University, Fairfax, Virginia; Division of Rheumatology and Pediatric Ophthalmology, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA.C. McCracken and J.G. Shantha contributed equally to this work. Research reported in this manuscript was supported by the National Eye Institute (NEI) Award Number K23EY021760 (STAH), K23EY030159 ( JGS), and the Rheumatology Research Foundation. STAH is also supported by NEI R01EY030521. SP is supported in part by a grant from the Marcus Foundation Inc., Atlanta. SY is a consultant for Santen and Clearside Biomedical, unrelated to this study. KARS is a consultant for Accordant, unrelated to this study. SP serves on the Macrophage Activation Syndrome Adjudication Committee for Novartis and is a Doximity Op-Med Fellow for 2021–22, unrelated to this study. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. S.T. Angeles-Han, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, 3333 Burnett Avenue, Cincinnati, OH 45229, USA; Department of Pediatrics, University of Cincinnati, Cincinnati, OH 45229, USA. Email: sheila.angeles-han@cchmc.org.
Carolyn Drews-Botsch
Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia; Francis I. Proctor Foundation for Research in Ophthalmology, and Department of Ophthalmology University of California, San Francisco, San Francisco, California; Department of Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska; Children's Healthcare of Atlanta, Atlanta, Georgia; Department of Ophthalmology, Stanford University, Stanford, California; Department of Genetics, Emory University School of Medicine, Atlanta, Georgia; Department of Global and Community Health, George Mason University, Fairfax, Virginia; Division of Rheumatology and Pediatric Ophthalmology, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA.C. McCracken and J.G. Shantha contributed equally to this work. Research reported in this manuscript was supported by the National Eye Institute (NEI) Award Number K23EY021760 (STAH), K23EY030159 ( JGS), and the Rheumatology Research Foundation. STAH is also supported by NEI R01EY030521. SP is supported in part by a grant from the Marcus Foundation Inc., Atlanta. SY is a consultant for Santen and Clearside Biomedical, unrelated to this study. KARS is a consultant for Accordant, unrelated to this study. SP serves on the Macrophage Activation Syndrome Adjudication Committee for Novartis and is a Doximity Op-Med Fellow for 2021–22, unrelated to this study. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. S.T. Angeles-Han, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, 3333 Burnett Avenue, Cincinnati, OH 45229, USA; Department of Pediatrics, University of Cincinnati, Cincinnati, OH 45229, USA. Email: sheila.angeles-han@cchmc.org.
Sheila T. Angeles-Han
Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia; Francis I. Proctor Foundation for Research in Ophthalmology, and Department of Ophthalmology University of California, San Francisco, San Francisco, California; Department of Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska; Children's Healthcare of Atlanta, Atlanta, Georgia; Department of Ophthalmology, Stanford University, Stanford, California; Department of Genetics, Emory University School of Medicine, Atlanta, Georgia; Department of Global and Community Health, George Mason University, Fairfax, Virginia; Division of Rheumatology and Pediatric Ophthalmology, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA.C. McCracken and J.G. Shantha contributed equally to this work. Research reported in this manuscript was supported by the National Eye Institute (NEI) Award Number K23EY021760 (STAH), K23EY030159 ( JGS), and the Rheumatology Research Foundation. STAH is also supported by NEI R01EY030521. SP is supported in part by a grant from the Marcus Foundation Inc., Atlanta. SY is a consultant for Santen and Clearside Biomedical, unrelated to this study. KARS is a consultant for Accordant, unrelated to this study. SP serves on the Macrophage Activation Syndrome Adjudication Committee for Novartis and is a Doximity Op-Med Fellow for 2021–22, unrelated to this study. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. S.T. Angeles-Han, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, 3333 Burnett Avenue, Cincinnati, OH 45229, USA; Department of Pediatrics, University of Cincinnati, Cincinnati, OH 45229, USA. Email: sheila.angeles-han@cchmc.org.
Data supplements
Data Supplement
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Relapse and Remission in Children With Chronic Noninfectious Uveitis Treated With Methotrexate
Courtney McCracken, Jessica G. Shantha, Steven Yeh, Kirsten Jenkins, Kelly A. Rouster-Stevens, Scott R. Lambert, Sampath Prahalad, Carolyn Drews-Botsch, Sheila T. Angeles-Han
The Journal of Rheumatology Aug 2022, jrheum.220007; DOI: 10.3899/jrheum.220007
Relapse and Remission in Children With Chronic Noninfectious Uveitis Treated With Methotrexate
Courtney McCracken, Jessica G. Shantha, Steven Yeh, Kirsten Jenkins, Kelly A. Rouster-Stevens, Scott R. Lambert, Sampath Prahalad, Carolyn Drews-Botsch, Sheila T. Angeles-Han
The Journal of Rheumatology Aug 2022, jrheum.220007; DOI: 10.3899/jrheum.220007